Holmium-Loaded PLLA Nanoparticles for Intratumoral Radiotherapy Via the TMT Technique: Preparation, Characterization, and Stability Evaluation after Neutron Irradiation

Hamoudeh, Misara; Fessi, Hatem; Salim, Hani; Barbos, D.

doi:10.1080/03639040801918623

Cited by 19 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Holmium acetylacetonate encapsulated in PLLA nanoparticles were irradiated in a neutron flux of 1.1 × 10 13 neutrons/cm 2 s for 1 h, yielding a specific activity of approximately 74.85 µCi/mg which was suitable for intratumoral administration by the targeted multitherapy (TMT) technique. 56 Bult et al reported holmium acetylacetonate nanoparticles for solid malignancies with a radioactivity of 324 µCi/mg after activation in a neutron flux of approximately 5 × 10 12 neutrons/cm 2 s for 1 h. 18 The radioactivities obtained here for the 166 Ho-MS nanoparticles are comparable to that of the previously reported nanoparticles; thus, a therapeutic level can be achieved.…”

supporting

confidence: 66%

See 1 more Smart Citation

Chemoradiotherapeutic wrinkled mesoporous silica nanoparticles for use in cancer therapy

et al. 2014

View full text Add to dashboard Cite

Over the last decade, the development and application of nanotechnology in cancer detection, diagnosis, and therapy have been widely reported. Engineering of vehicles for the simultaneous delivery of chemo- and radiotherapeutics increases the effectiveness of the therapy and reduces the dosage of each individual drug required to produce an observable therapeutic response. We here developed a novel chemoradiotherapeutic 1,2-dioleoyl-sn-glycero-3-phosphocholine lipid coated/uncoated platinum drug loaded, holmium-containing, wrinkled mesoporous silica nanoparticle. The materials were characterized with TEM, FTIR, 1H NMR, energy dispersive x-ray, inductively coupled plasma-mass spectrometry, and zeta potential measurements. In vitro platinum drug release from both lipid coated and uncoated chemoradiotherapeutic wrinkled mesoporous silica are reported. Various kinetic models were used to analyze the release kinetics. The radioactivity of the chemoradiotherapeutic nanocarriers was measured after neutron-activation.

show abstract

supporting

confidence: 66%

“…55 Hamoudeh et al reported 165 Ho(AcAc) 3 encapsulated in poly-l-lactide (PLLA) nanoparticles with a holmium content of 18% w/w. 56 Cacaina et al reported SiO 2 xerogels containing holmium with 15.8 (w/w). 57 metastases.…”

mentioning

confidence: 99%

Chemoradiotherapeutic wrinkled mesoporous silica nanoparticles for use in cancer therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The high density of these microparticles (3.2 g/cm 3 ), which on occasion resulted in particle settling after intracatheter administration, and the lack of photon emissions by 90 Y, which prevented quantitative imaging, led to the development of other neutron-activatable materials. Microparticles composed of lower-density polymers, including polylactic acid (5-7), alginate (8), and chitosan (9) containing 166 Ho, as well as nanosized carrier materials containing stable 165 Ho for subsequent neutron activation to 166 Ho (10)(11)(12), have also been reported. 166 Ho is an attractive radionuclide for radiotherapeutic applications.…”

mentioning

confidence: 99%

Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer

et al. 2012

View full text Add to dashboard Cite

Mesoporous silica nanoparticles (MSNs) were explored as a carrier material for the stable isotope 165 Ho and, after neutron capture, its subsequent therapeutic radionuclide, 166 Ho (half-life, 26.8 h), for use in radionuclide therapy of ovarian cancer metastasis. Methods: 165 Ho-MSNs were prepared using 165 Ho-acetylacetonate and MCM-41 silica particles, and stability was determined after irradiation in a nuclear reactor (reactor power, 1 MW; thermal neutron flux of approximately 5.5 · 10 12 neutrons/cm 2 Ás). SPECT/ CT and tissue biodistribution studies were performed after intraperitoneal administration of 166 Ho-MSNs to SKOV-3 ovarian tumor-bearing mice. Radiotherapeutic efficacy was studied by using PET/CT with 18 F-FDG to determine tumor volume and by monitoring survival. Results: The holmium-MSNs were able to withstand long irradiation times in a nuclear reactor and did not release 166 Ho after significant dilution. SPECT/CT images and tissue distribution results revealed that 166 Ho-MSNs accumulated predominantly in tumors (32.8% 6 8.1% injected dose/g after 24 h; 81% 6 7.5% injected dose/g after 1 wk) after intraperitoneal administration. PET/CT images showed reduced 18 F-FDG uptake in tumors, which correlated with a marked increase in survival after treatment with approximately 4 MBq of 166 Ho-MSNs. Conclusion: The retention of holmium in nanoparticles during irradiation and in vivo after intraperitoneal administration as well as their efficacy in extending survival in tumor-bearing mice underscores their potential as a radiotherapeutic agent for ovarian cancer metastasis.

show abstract

“…The NPs were irradiated in a nuclear reactor with a neutron flux of 1.1 × 10 [13] n/cm 2 /s for 1 h, which yielded a specific activity of about 27.4 GBq/g of NPs being sufficient for our desired application. These RINPs may represent a novel nanoparticle-based radiopharmaceutical for intratumoral radiotherapy [137,138].…”

Section: Active Targeting Radioactive Nanoparticlesmentioning

confidence: 99%

Radioimmunonanoparticles for Cancer Imaging and Therapy

Natarajan

2011

Nanoplatform‐Based Molecular Imaging

View full text Add to dashboard Cite

Holmium-Loaded PLLA Nanoparticles for Intratumoral Radiotherapy Via the TMT Technique: Preparation, Characterization, and Stability Evaluation after Neutron Irradiation

Cited by 19 publications

References 35 publications

Chemoradiotherapeutic wrinkled mesoporous silica nanoparticles for use in cancer therapy

Chemoradiotherapeutic wrinkled mesoporous silica nanoparticles for use in cancer therapy

Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer

Radioimmunonanoparticles for Cancer Imaging and Therapy

Contact Info

Product

Resources

About